• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Geriatric Care >Glyphozines and treatment of cardiac disease
【24h】

Glyphozines and treatment of cardiac disease

机译：甘酚和治疗心脏病

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Glyphozines also called SGLT2 inhibitors, are a new class of agents that inhibit reabsorption of glucose in the kidney, in proximal tubules, and therefore lower blood sugar. They act by inhibiting sodiumglucose transport protein 2 (SGLT2). Glyphozines are used in the treatment of type II diabetes mellitus. In studies with canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure. In addition to regulate blood glucose, recent studies have shown that glyphozines have important positive cardiovascular benefits, such as weight loss, decreased volaemia and PA, reduced triglycerides, natriuresis and improved endothelial wall dysfunction. Clinical studies have shown reduction in deaths from cardiovascular events among diabetic patients treated with glyphozines. At the moment these drugs are being studied for an extension of the therapeutic indication also for cardiovascular diseases such as heart failure. In this review, we discuss the class of SGLT2 inhibitors in the treatment of diabetes, and studies focused on their possible role in the treatment of cardiac disease.
机译：草甘膦也称为SGLT2抑制剂，是一种新的一种新的药剂，抑制肾脏中葡萄糖的葡萄糖，近端小管，因此降低血糖。它们通过抑制钠葡萄糖转运蛋白2（SGLT2）起作用。草甘膦用于治疗II型糖尿病。在用蜜胶中的研究中，发现该类的成员，发现药物治疗血糖控制，以及减轻体重和收缩性和舒张血压。除了调节血糖外，最近的研究表明，大理碱具有重要的阳性心血管益处，如体重减轻，减少的血管血症和PA，甘油三酯，Natri resis和改进的内皮壁功能障碍。临床研究显示糖尿病患者的心血管事件中死亡减少了糖尿病患者的糖尿病患者。目前正在研究这些药物的治疗指示的延伸，也用于心脏血管疾病，如心脏衰竭。在这篇综述中，我们讨论了治疗糖尿病的SGLT2抑制剂类，研究重点关注其在治疗心脏病中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号